retatrutide clinical trial updates FDA Approval Status: July 2026 Update Eli Lilly infiltrates anti-obesity market
Description
Introduction The world of pharmaceuticals is buzzing with excitement over a new class of drugs - GLP-1 agonists - and their potential in the fight against obesity
But a new study finds the majority of people who use these drugs quit after just two years
GLP-1
GLP-1 SM (GLP-1 receptor agonist) research-grade peptide, 99.52% HPLC purity, third-party endotoxin screened, lot 24-2433
